You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

FDA Approvals: Nplate, Aloxi, Vidaza

  • Authors: News Author: Yael Waknine
    CME Author: Yael Waknine
  • CME Released: 9/4/2008
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 9/4/2009
Start Activity


Target Audience and Goal Statement

This article is intended for primary care clinicians, hematologists, oncologists, and other specialists who care for patients with chronic immune thrombocytopenic purpura, higher-risk myelodysplastic syndromes, or patients who require moderately emetogenic chemotherapy.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  1. Identify the potential benefits of romiplostim therapy in chronic immune thrombocytopenic purpura.
  2. Describe the appropriate use of palonosetron HCl capsules.
  3. Describe new benefits of azacitidine injection in higher-risk myelodysplastic syndromes.

 


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Yael Waknine

    Yael Waknine is a freelance writer for Medscape.

    Disclosures

    Disclosure: Yael Waknine has disclosed no relevant financial relationships.

Editor(s)

  • Brande Nicole Martin

    Brande Nicole Martin is the News CME editor for Medscape Medical News.

    Disclosures

    Disclosure: Brande Nicole Martin has disclosed no relevant financial information.

Reviewer(s)

  • Laurie Barclay, MD

    Laurie Barclay, MD is a freelance reviewer and writer for Medscape.

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

CME Author(s)

  • Yael Waknine

    Yael Waknine is a freelance writer for Medscape.

    Disclosures

    Disclosure: Yael Waknine has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape Medical News has been reviewed and is acceptable for up to 350 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 09/01/08. Term of approval is for 1 year from this date. This activity is approved for 0.25 Prescribed credits. Credit may be claimed for 1 year from the date of this activity.

    Note: Total credit is subject to change based on topic selection and article length.


    AAFP Accreditation Questions

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME

FDA Approvals: Nplate, Aloxi, Vidaza

Authors: News Author: Yael Waknine CME Author: Yael WaknineFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 9/4/2008

Valid for credit through: 9/4/2009

processing....

September 4, 2008 — The US Food and Drug Administration (FDA) has approved romiplostim subcutaneous injection for the treatment of chronic immune thrombocytopenic purpura, palonosetron HCl capsules for the prevention of chemotherapy-induced nausea and vomiting, and an expanded approval for azacitidine injection based on new overall survival rates in patients with higher-risk myelodysplastic syndromes.

Romiplostim Injection (Nplate) Approved for Thrombocytopenia in Patients With ITP

On August 22, the FDA approved romiplostim subcutaneous injection (Nplate; Amgen, Inc) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Romiplostim is a therapeutic fusion protein that combines attributes of both peptides and antibodies but is distinct from each. It mimics naturally occurring thrombopoietin (TPO), acting on TPO receptors to activate intracellular transcriptional pathways that lead to increased platelet production.

"Until now, patients suffering from chronic ITP have had limited available treatment options, many of which are often unsuitable for long-term use due to side effects and tolerability issues," said David J. Kuter, MD, chief of Hematology at Massachusetts General Hospital, Boston, in a company news release. "Nplate represents the first long-term treatment for adult chronic ITP patients, providing a new treatment approach for this chronic disease."

The approval was based on data from two 24-week double-blind, placebo-controlled, phase 3 clinical studies of 125 patients with baseline platelet counts of 30,000 x 109/L or less who had completed at least 1 previous therapy.

Results showed that romiplostim therapy yielded significantly increased overall response rates relative to placebo; the difference was higher in patients without splenectomy (88% vs 14%) vs patients with splenectomy (79% vs 0%; P < .05 for both).

Moreover, 61% of patients without splenectomy and 38% of patients with splenectomy achieved a durable response while receiving romiplostim, defined as at least 6 weekly platelet counts of 50,000 x 109/L or greater during the last 8 weeks in the absence of rescue medication at any time.

Combined data from both studies revealed that romiplostim therapy also significantly reduced the risk for serious (≥ grade 2 severity) bleeding events (15% vs placebo, 34%).

These findings were supported by long-term data from an open-label extension study (n = 100), in which the majority of responding patients maintained platelet counts greater than 50,000 x 109/L during a median treatment period of 60 weeks (maximum, 96 weeks).

The recommended starting dose for romiplostim is 1 µg/kg administered by subcutaneous injection once weekly and then adjusted by increments of 1 µg/kg until a platelet count of 50 x 109/L or greater is achieved. In clinical studies, a median dose of 2 µg/kg was required to achieve and maintain this response. Treatment should be discontinued if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks of therapy at the maximal weekly dose of 10 µg/kg.

In the placebo-controlled studies, headache was the most commonly reported adverse reaction (35% vs placebo, 32%). Other adverse events included arthralgia, dizziness, insomnia, myalgia, pain in the extremity, abdominal pain, shoulder pain, dyspepsia, and paresthesia.

Serious adverse events included bone marrow reticulin deposition and worsening thrombocytopenia after discontinuation of romiplostim therapy. Other risks include blood clots from excessive platelet formation and the potential for leukemia in patients with myelodysplasia.

Because of these risks, romiplostim will only be available through a restricted distribution program called the Network of Experts Understanding and Supporting Nplate and Patients, which has been developed as part of a risk evaluation and mitigation strategy that will also provide patient support and education and assist with safety data collection.

Oral Palonosetron (Aloxi) Approved for Prevention of Chemotherapy-Induced Nausea and Vomiting

On August 22, the FDA approved an oral capsule formulation of palonosetron HCl (Aloxi; Eisai Corp) for the prevention of acute nausea and vomiting after initial and repeated courses of moderately emetogenic chemotherapy.

The approval was based primarily on data from a multicenter, randomized, double-blind, active-control clinical study of 635 patients, in which complete response was defined as having no emetic episodes or requirements for rescue medication during the acute phase (0 - 24 hours) or delayed phases (24 - 120 hours).

Acute-phase results showed that oral palonosetron (0.5 mg) was noninferior to a 0.25-mg dose of the previously approved intravenous (IV) formulation (76.3% vs 70.4%; 2-sided 98.3% confidence interval, –6.5% to 18.2%). However, statistical noninferiority was not demonstrated during the delayed phase (62.5% vs 65.4%; 98.3% confidence interval, –16.3% to 10.5%).

The recommended dose is one 0.5-mg capsule administered approximately 1 hour before the start of chemotherapy. In the study, the most commonly reported adverse events were headache (3.7% vs 0.25-mg IV, 8.6%) and constipation (0.6% vs 0.25-mg IV, 3.1%).

Palonosetron injection previously was approved by the FDA for the prevention of acute and delayed nausea and vomiting associated with initial and repeated courses of moderately emetogenic chemotherapy and for the prevention of acute nausea and vomiting associated with initial and repeated courses of highly emetogenic chemotherapy. The recommended dose for the injection is 0.25 mg administered IV approximately 30 minutes before chemotherapy.

Azacitidine (Vidaza) Extends Survival in Patients With Higher-Risk Myelodysplastic Syndromes

On August 20, the FDA approved an expanded indication for azacitidine injection (Vidaza; Celgene Corp) that reflects new overall survival data achieved in the AZA-001 study of patients with higher-risk myelodysplastic syndromes (MDS).

"We are very encouraged by the Vidaza data from the AZA-001 trial. This trial showed, for the first time, a drug can extend survival for MDS patients," said John Huber, executive director of the Aplastic Anemia and MDS International Foundation, in a news release. "We are excited to see that in this trial Vidaza also reduced the need for blood transfusions."

According to a company news release, AZA-001 is the largest international randomized phase 3 controlled study ever conducted in higher-risk MDS. Results showed that use of azacitidine for a median of 9 cycles rather than conventional-care regimens (CCR) significantly improved median overall survival (24.5 months vs 15 months; P = .0001; hazard ratio, 0.58; 95% confidence interval, 0.43 - 0.77) and almost doubled the 2-year survival rate (50.8% vs 26.2%). Survival benefit was observed across relevant patient subgroups, including elderly patients (aged > 65 years), those with acute myelogenous leukemia, and patients with poor risk cytogenetics.

Furthermore, nearly half (45%) of patients who were transfusion dependent at baseline achieved transfusion independence (vs conventional-care regimens, 11.4%); results were durable, and the median duration of transfusion independence was 13.0 months.

In the study, the most commonly reported adverse events in azacitidine-treated patients were thrombocytopenia (69.7%), neutropenia (65.7%), and anemia (51.4%).

"The clinical data from this randomized Phase III controlled study demonstrated that patients with higher-risk MDS treated with VIDAZA benefit from a significant survival advantage, a critical measure of a drug's effectiveness," said Lewis Silverman, MD, of the Mount Sinai Medical Center in New York City, in a company news release. "Additionally, the efficacy and safety profile of VIDAZA allows for long-term therapy in patients with higher-risk MDS, underscoring the ability to treat until disease progression for optimal survival benefit."

Dr. Silverman was the lead author and principal investigator for the original azacitidine approval study (CALGB 9221) and an author and investigator of the international AZA-001 survival trial.

Azacitidine was approved by the FDA in May 2004 for the treatment of all 5 MDS subtypes, including refractory anemia or refractory anemia with sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.

NPlate Prescribing Information

Aloxi Prescribing Information

Vidaza Prescribing Information

Pearls for Practice

  • The FDA has approved romiplostim once-weekly subcutaneous injection for the treatment of refractory chronic immune thrombocytopenic purpura in patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
  • Palonosetron HCl capsules have been approved for the prevention of acute nausea and vomiting after initial and repeated courses of moderately emetogenic chemotherapy. The recommended dose is one 0.5-mg capsule administered approximately 1 hour before the start of chemotherapy.
  • Data from a large study of higher-risk myelodysplastic syndromes have revealed that azacitidine significantly improves survival vs conventional-care regimens and almost doubles the 2-year survival rate. Nearly half of patients dependent on transfusion achieved independence.

CME Test

  • Print